Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358626 | 1.00 | CYP1A2 (1.00) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29695523 | 0.85 | CYP1A2 (0.74) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL763168 | 0.85 | CYP1A2 (0.74) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6902600 | 0.82 | RAB9A (0.72) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Citric Acid SCHEMBL30368958 | 0.82 | CYP1A2 (0.67) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29579885 | 0.81 | CYP1A2 (0.69) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL982104 | 0.81 | CYP1A2 (0.69) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1838349 | 0.81 | RAB9A (0.70) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30947438 | 0.81 | LMNA (0.78) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11049972 | 0.81 | CYP1A2 (0.68) | CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119789670-A | Perovskite solar cell and preparation method thereof | 中建科工集团有限公司 | 2025-04-08 | — | — | CN | claimed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | claimed |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | WRIGHT STATE UNIVERSITY (US) | 2017-10-19 | — | — | US | claimed |
| EP-1513870-A4 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS AND METHODS AND PRODUCTS FOR DETECTING AND/OR IDENTIFYING SAME | CHILDRENS HOSP MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1513870-A2 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS AND METHODS AND PRODUCTS FOR DETECTING AND/OR IDENTIFYING SAME | Children's Hospital Medical Center (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20040029773-A1 | Use of 1-ebio in the treatment of bipolar disorders | SMITHKLINE BEECHAM CORPORATION | 2004-02-12 | — | — | US | claimed |
| WO-2003102140-A2 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | claimed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | claimed |
| EP-1330247-A1 | USE OF 1-EBIO IN THE TREATMENT OF BIPOLAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-07-30 | — | — | EP | claimed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | claimed |
| WO-2002036121-A1 | USE OF 1-EBIO IN THE TREATMENT OF BIPOLAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2002-05-10 | — | — | WO | claimed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | disclosed |
| US-5053411-A | Analgesics | ANAQUEST, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| WO-1991001379-A1 | METHOD OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS | ONCOGENE SCIENCE, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| EP-0396282-A2 | N-aryl-N-[4-(heterocyclicalkyl) piperidinyl]amides and pharmaceutical compositions and methods employing such compounds | BOC, INC. (US) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | CYP1A2 2412/4885MEN1 3761/4885KMT2A 389/4885 |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | KCNN3, KCNN2, KCNN1 | CYP1A2 4841/4885MEN1 4559/4885KMT2A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.